ClinicalTrials.gg
CompletedNCT03551730Updated Feb 22, 2023Results posted

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

A Phase 2 interventional study of PRT064445/Enoxaparin and Placebo/Enoxaparin in Healthy Volunteers, sponsored by Portola Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-22.

Sponsored by Portola Pharmaceuticals (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the ability of PRT064445 to reverse the effects of several blood thinner drugs on laboratory tests. The study also is evaluating the blood levels of PRT064445 given at different doses.

Read the detailed description

A randomized, double-blind, vehicle-controlled study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously administered PRT064445 after dosing to steady state with one of four direct/indirect factor Xa (fXa) inhibitors in healthy volunteers.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Portola Pharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.

First submitted before Portola Pharmaceuticals became part of AstraZeneca.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy men or women between the ages of 18 and 45 years old

Exclusion criteria

Exclusion Criteria:

  • History (including family history) or symptoms of, or risk factors for bleeding
  • History (including family history) of or risk factors for a hypercoagulable or thrombotic condition
  • Absolute/relative to anticoagulation or treatment with specific anticoagulants
  • History of major surgery, severe trauma or bone fracture within 3 months prior to dosing; or planned surgery within 1 month after dosing.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Module 3 (210 mg bolus) original

    210 mg PRT064445 given as a single IV bolus

    Combination Product: PRT064445/Enoxaparin · Combination Product: Placebo/Enoxaparin

  • Experimental
    Module 3 (420 mg bolus) original

    420 mg PRT064445 given as a single IV bolus

    Combination Product: PRT064445/Enoxaparin · Combination Product: Placebo/Enoxaparin

  • Experimental
    Module 3 (210 mg) lyophilized

    210 mg PRT064445 (lyophilized formulation) given as a single IV bolus

    Combination Product: PRT064445/Enoxaparin · Combination Product: Placebo/Enoxaparin

  • Placebo comparator
    Module 3 Placebo

    Placebo administered intravenously (IV) as a bolus.

    Drug: Placebo

Interventions

  • Combination productPRT064445/Enoxaparin

    Drug pages: PRT064445 · Enoxaparin

    Also known as: Andexanet

  • Combination productPlacebo/Enoxaparin
  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Efficacy:Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration Activity

    Anti-fXa activity was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Anti-fXa activity was measured using a commercial kit (Coamatic Heparin-82 33 9363, DiaPharma)

    Time frame: Baseline to 2 minutes following the end of andexanet/placebo administration

Secondary outcomes

  1. Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration

    Thrombin generation was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Thrombin generation was measured using a TF-initiated thrombin generation assay.

    Time frame: Baseline to 2 minutes following the end of andexanet/placebo administration

  2. Andexanet Maximum Observed Plasma Concentration (Cmax)

    Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Cmax was taken directly from the raw data.

    Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

  3. Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )

    Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. AUC0-inf was calculated using a non-compartmental approach

    Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

  4. Andexanet Time of Maximum Observed Plasma Concentration (Tmax)

    Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Tmax was taken directly from the raw data.

    Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

  5. Andexanet Apparent Terminal Elimination Half-life (t1/2)

    Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay.t1/2 was determined by linear regression of the log concentration on the terminal portion of the plasma concentration-time curve.

    Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

  6. Andexanet Total Systemic Clearance (CL)

    Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. CL was calculated using a non-compartmental approach.

    Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

  7. Andexanet Total Volume of Distribution (Vss)

    Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Vss was calculated using a non-compartmental approach.

    Time frame: Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.

07

Results

Posted Aug 13, 2018

Participant flow

Subject recruitment occurred at investigative site in the US between August 2013 through November 2013

Participant flow — Overall Study
MilestonePlaceboModule 3 (210 mg Bolus) OriginalModule 3 (420 mg Bolus) OriginalModule 3 (210 mg) Lyophilized
Started9666
Completed8666
Not completed1000
Withdrew: Adverse event1000

Outcome measures

PrimaryEfficacy:Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration Activity

Anti-fXa activity was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Anti-fXa activity was measured using a commercial kit (Coamatic Heparin-82 33 9363, DiaPharma)

Time frame:
Baseline to 2 minutes following the end of andexanet/placebo administration
Reported as:
Mean · Percent change in anti-fXa activity
Efficacy:Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration Activity
Percent change in anti-fXa activityPlaceboModule 3 (210 mg Bolus) OriginalModule 3 (420 mg Bolus) OriginalModule 3 (210 mg) Lyophilized
Efficacy:Percent Change From Baseline in Anti-fXa Activity at 2 Mins Following Andexanet/Placebo Administration Activity-3.57 ± 12.80-70.80 ± 6.98-60.83 ± 8.39-69.85 ± 7.46
Statistical analysis
  • Placebo vs Module 3 (210 mg Bolus) Original · ANCOVA · p = <0.0001 · Least squares means (difference): -0.23
  • Placebo vs Module 3 (420 mg Bolus) Original · ANCOVA · p = <0.0001 · Least squares means (difference): -0.20
  • Placebo vs Module 3 (210 mg) Lyophilized · ANCOVA · p = <0.0001 · Least squares means (difference): -0.23
SecondaryEfficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration

Thrombin generation was measured immediately prior to (Baseline) and at 2 mins following andexanet/placebo administration. Thrombin generation was measured using a TF-initiated thrombin generation assay.

Time frame:
Baseline to 2 minutes following the end of andexanet/placebo administration
Reported as:
Mean · Percent change in thrombin generation
Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration
Percent change in thrombin generationPlaceboModule 3 (210 mg Bolus) OriginalModule 3 (420 mg Bolus) OriginalModule 3 (210 mg) Lyophilized
Efficacy: Percent Change From Baseline in Thrombin Generation at 2 Mins Following Andexanet/Placebo Administration3.48 ± 15.16236.34 ± 15.127107.48 ± 73.30172.7 ± 74.301
Statistical analysis
  • Placebo vs Module 3 (210 mg Bolus) Original · ANCOVA · p = 0.1529 · Least squares means (difference): 53922.58
  • Placebo vs Module 3 (420 mg Bolus) Original · ANCOVA · p = <0.0001 · Least squares means (difference): 124993.1
  • Placebo vs Module 3 (210 mg) Lyophilized · ANCOVA · p = 0.0032 · Least squares means (difference): 96385.09
SecondaryAndexanet Maximum Observed Plasma Concentration (Cmax)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Cmax was taken directly from the raw data.

Time frame:
Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Reported as:
Mean · ng/mL
Andexanet Maximum Observed Plasma Concentration (Cmax)
ng/mLPlaceboModule 3 (210 mg Bolus) OriginalModule 3 (420 mg Bolus) OriginalModule 3 (210 mg) Lyophilized
Andexanet Maximum Observed Plasma Concentration (Cmax)—32000 ± 732055800 ± 605042700 ± 14400
SecondaryAndexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. AUC0-inf was calculated using a non-compartmental approach

Time frame:
Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Reported as:
Mean · ng*hr/mL
Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )
ng*hr/mLPlaceboModule 3 (210 mg Bolus) OriginalModule 3 (420 mg Bolus) OriginalModule 3 (210 mg) Lyophilized
Andexanet Area Under the Drug Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-inf )—33600 ± 428063900 ± 888040900 ± 12300
SecondaryAndexanet Time of Maximum Observed Plasma Concentration (Tmax)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Tmax was taken directly from the raw data.

Time frame:
Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Reported as:
Median · hr
Andexanet Time of Maximum Observed Plasma Concentration (Tmax)
hrPlaceboModule 3 (210 mg Bolus) OriginalModule 3 (420 mg Bolus) OriginalModule 3 (210 mg) Lyophilized
Andexanet Time of Maximum Observed Plasma Concentration (Tmax)—0.18 (0.16 to 0.35)0.29 (0.27 to 0.54)0.17 (0.17 to 0.19)
SecondaryAndexanet Apparent Terminal Elimination Half-life (t1/2)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay.t1/2 was determined by linear regression of the log concentration on the terminal portion of the plasma concentration-time curve.

Time frame:
Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Reported as:
Mean · hr
Andexanet Apparent Terminal Elimination Half-life (t1/2)
hrPlaceboModule 3 (210 mg Bolus) OriginalModule 3 (420 mg Bolus) OriginalModule 3 (210 mg) Lyophilized
Andexanet Apparent Terminal Elimination Half-life (t1/2)—5.28 ± 1.996.11 ± 2.348.36 ± 7.46
SecondaryAndexanet Total Systemic Clearance (CL)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. CL was calculated using a non-compartmental approach.

Time frame:
Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Reported as:
Mean · L/hr
Andexanet Total Systemic Clearance (CL)
L/hrPlaceboModule 3 (210 mg Bolus) OriginalModule 3 (420 mg Bolus) OriginalModule 3 (210 mg) Lyophilized
Andexanet Total Systemic Clearance (CL)—6.34 ± 0.8706.69 ± 0.9915.56 ± 1.76
SecondaryAndexanet Total Volume of Distribution (Vss)

Plasma concentrations of andexanet was determined using a validated method that involved analysis of citrated human plasma by an electrochemiluminescent assay. Vss was calculated using a non-compartmental approach.

Time frame:
Blood was collected at predose, 0.033, 0.2, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4.5, 5.5, 6.5, 7.5, 8.5 and 14.5 hours postdose.
Reported as:
Mean · L
Andexanet Total Volume of Distribution (Vss)
LPlaceboModule 3 (210 mg Bolus) OriginalModule 3 (420 mg Bolus) OriginalModule 3 (210 mg) Lyophilized
Andexanet Total Volume of Distribution (Vss)—9.86 ± 2.619.62 ± 1.139.69 ± 4.16

Adverse events

Collected over ~7 weeks. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/8 (0%)5/8 (62.5%)
Module 3 (210 mg Andexanet) Original Formulation—0/6 (0%)4/6 (66.7%)
Module 3 (420 mg Andexanet) Original Forumulation—0/6 (0%)4/6 (66.7%)
Module 3 (210 mg Andexanet ) Lyophilized—0/6 (0%)5/6 (83.3%)
Most frequent other events
Showing 10 of 31
Most frequent other events
EventPlaceboModule 3 (210 mg Andexanet) Original FormulationModule 3 (420 mg Andexanet) Original ForumulationModule 3 (210 mg Andexanet ) Lyophilized
Abdominal tendernessGastrointestinal disorders3/80/60/60/6
Dry mouthGastrointestinal disorders0/80/62/60/6
Infusion related reactionInjury, poisoning and procedural complications0/81/61/62/6
Procedural site reactionInjury, poisoning and procedural complications2/81/62/61/6
DizzinessNervous system disorders0/80/62/60/6
Procedural painInjury, poisoning and procedural complications2/81/61/60/6
Abdominal painGastrointestinal disorders0/80/60/61/6
DyspepsiaGastrointestinal disorders0/80/61/60/6
NauseaGastrointestinal disorders1/80/61/61/6
ToothacheGastrointestinal disorders0/80/61/60/6

Baseline characteristics

27 subjects were enrolled in Module 3

Age, Continuous
Age, Continuous(years)PlaceboModule 3 (210 mg Bolus) OriginalModule 3 (420 mg Bolus) OriginalModule 3 (210 mg) LyophilizedTotal
Mean33.7 ± 5.5933.2 ± 8.3032.5 ± 5.0935.7 ± 8.6633.7 ± 6.60
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboModule 3 (210 mg Bolus) OriginalModule 3 (420 mg Bolus) OriginalModule 3 (210 mg) LyophilizedTotal
Female520310
Male446317
08

Study locations

1 site
  • Tempe, Arizona 85283, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2018
First posted
Jun 11, 2018
Start
Dec 2012
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Aug 13, 2018
Last update
Feb 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03551730
Responsible party
Sponsor
First posted
Jun 11, 2018
Start date
Dec 2012
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Aug 13, 2018
Last update
Feb 22, 2023

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PRT064445 · Enoxaparin

Start the discussion